Rekah Pharmaceutical Industry Ltd (REKA) Fair Value & Analysis
Healthcare · Il · Market cap 122M ILA
Fair value as of: Jun 24, 2026
From 14 valuation models · updated 5 days ago
Share price −6.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 10.35 ILA – 13.87 ILA · fair‑value band 7.28 ILA – 12.63 ILA · the 10.79 ILA price screens above the 8.68 ILA fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Rekah Pharmaceutical Industry Ltd (REKA) currently trades at 10.79 ILA, while our model-based Fair Value estimate is 8.68 ILA — implying the stock looks roughly 19.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Rekah Pharmaceutical Industry Ltd generated revenue of 304M ILA at a net margin of -6.1%. Revenue grew 4.2% year over year. It earns a return on equity of -12.3%. Net debt stands at 128M ILA. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeutic fields, such as urinary tract pain, steroid anti-inflammatories, cough, expectoration and bronchitis, motion sickness, runny nose and congestion, skin disinfection, wounds, burns and insect bites, eye infections, glaucoma, dryness, allergies, fever and pain relief, mouth, depression and anxiety, muscle and joint pain, antibiotics, fungal infections, anemia and nutritional deficits, ear pain, babies and children, etc. The company was founded in 1947 and is based in Holon, Israel.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Rekah Pharmaceutical Industry Ltd reported revenue of 301M ILA in FY2025 versus 264M ILA in FY2021, a compound +3.3%/yr. Reported net income was −18.1M ILA in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Rekah Pharmaceutical Industry Ltd (REKA) undervalued?
What is the fair value of REKA?
What is the quality score of REKA?
What is the revenue of Rekah Pharmaceutical Industry Ltd (REKA)?
What is the net profit margin of REKA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.